Reductil produces its therapeutic effect by norepinephrine, serotonin and dopamine reuptake inhibition. Reductil exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound Reductil is a potent inhibitor of serotonin and norepinephrine reuptake in vivo. However metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vivo and in vitro.